Chester County News and Community Website
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), to …
Johnson & Johnson Receives FDA Approval for Monthly RYBREVANT FASPRO Dosing Read More
PHILADELPHIA, PA — A jury in the Philadelphia Court of Common Pleas awarded $250,000 against Johnson & Johnson (NYSE: JNJ), finding the company’s talc-based baby powder products contributed to the …
Philadelphia Jury Awards $250,000 in J&J Talc Cancer Trial Read More
What This Means for You More than 500 new jobs are expected in Montgomery County over the next 12 years. The state will provide up to $41.5 million in financial …
Johnson & Johnson to Invest $1 Billion in Montgomery County Cancer Drug Facility Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved a new frontline treatment option for adults newly diagnosed with multiple myeloma who …
FDA Clears Johnson & Johnson Myeloma Combo, Expanding Frontline Care Read More
HARRISBURG, PA — Pennsylvania is quietly pulling off what many states only promise: keeping new businesses alive long enough to thrive. New federal data shows that 56 percent of companies …
Pennsylvania’s Business Boom Defies the Odds as Survival Rates Soar Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …
J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the first and only subcutaneous therapy for patients with EGFR-mutated non-small …
FDA Clears Five-Minute Lung Cancer Shot, Redefining EGFR Treatment Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …
FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for adults with …
FDA Approves First Treatment for High-Risk Smoldering Multiple Myeloma Read More